We are developing a platform for chimeric antigen receptor (CAR) technologies that allows for the production of multiple target-specific constructs.

CAR immune cell therapy is based on the selective ex vivo expansion of immune cells derived from patient peripheral blood and consists of four key steps:

  1. Harvesting the immune cells from the patient’s blood.
  2. Genetically engineering immune cells to express cancer-specific receptors.
  3. Increasing the number of engineered immune cells through ex vivo expansion.
  4. Infusing the functional cancer-specific immune cells back into the patient.

Through this process we are able to engineer immune cells that are capable of recognizing and killing cancer cells based on their proteins expressed on the surface of the cancer cell.